vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and Spire Global, Inc. (SPIR). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $15.8M, roughly 1.5× Spire Global, Inc.). Spire Global, Inc. runs the higher net margin — -176.6% vs -416.2%, a 239.5% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -26.9%). Spire Global, Inc. produced more free cash flow last quarter ($-16.2M vs $-69.4M). Over the past eight quarters, Intellia Therapeutics, Inc.'s revenue compounded faster (-10.8% CAGR vs -32.6%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Spire Global, Inc. is a space-to-cloud data and analytics company that specializes in the tracking of global data sets powered by a large constellation of nanosatellites, such as the tracking of maritime, aviation and weather patterns.
NTLA vs SPIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $15.8M |
| Net Profit | $-95.8M | $-28.0M |
| Gross Margin | — | 40.2% |
| Operating Margin | -428.9% | -164.1% |
| Net Margin | -416.2% | -176.6% |
| Revenue YoY | 78.8% | -26.9% |
| Net Profit YoY | 25.7% | 42.7% |
| EPS (diluted) | $-0.81 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $15.8M | ||
| Q3 25 | $13.8M | $12.7M | ||
| Q2 25 | $14.2M | $19.2M | ||
| Q1 25 | $16.6M | $23.9M | ||
| Q4 24 | $12.9M | $21.7M | ||
| Q3 24 | $9.1M | $28.6M | ||
| Q2 24 | $7.0M | $25.4M | ||
| Q1 24 | $28.9M | $34.8M |
| Q4 25 | $-95.8M | $-28.0M | ||
| Q3 25 | $-101.3M | $-19.7M | ||
| Q2 25 | $-101.3M | $119.6M | ||
| Q1 25 | $-114.3M | $-20.7M | ||
| Q4 24 | $-128.9M | $-48.8M | ||
| Q3 24 | $-135.7M | $-12.5M | ||
| Q2 24 | $-147.0M | $-16.6M | ||
| Q1 24 | $-107.4M | $-25.5M |
| Q4 25 | — | 40.2% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 48.9% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 32.4% | ||
| Q3 24 | — | 44.5% | ||
| Q2 24 | — | 43.0% | ||
| Q1 24 | — | 26.5% |
| Q4 25 | -428.9% | -164.1% | ||
| Q3 25 | -808.9% | -166.1% | ||
| Q2 25 | -772.2% | -122.7% | ||
| Q1 25 | -726.6% | -106.5% | ||
| Q4 24 | -1059.9% | -144.1% | ||
| Q3 24 | -1589.0% | -48.0% | ||
| Q2 24 | -1998.6% | -48.6% | ||
| Q1 24 | -394.0% | -34.4% |
| Q4 25 | -416.2% | -176.6% | ||
| Q3 25 | -735.2% | -155.3% | ||
| Q2 25 | -710.8% | 623.4% | ||
| Q1 25 | -687.6% | -86.5% | ||
| Q4 24 | -1001.2% | -225.2% | ||
| Q3 24 | -1489.5% | -43.7% | ||
| Q2 24 | -2112.6% | -65.2% | ||
| Q1 24 | -371.3% | -73.3% |
| Q4 25 | $-0.81 | $-0.85 | ||
| Q3 25 | $-0.92 | $-0.61 | ||
| Q2 25 | $-0.98 | $3.72 | ||
| Q1 25 | $-1.10 | $-0.77 | ||
| Q4 24 | $-1.27 | $-1.93 | ||
| Q3 24 | $-1.34 | $-0.50 | ||
| Q2 24 | $-1.52 | $-0.68 | ||
| Q1 24 | $-1.12 | $-1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $112.9M |
| Total Assets | $842.1M | $211.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $81.8M | ||
| Q3 25 | $511.0M | $96.8M | ||
| Q2 25 | $459.7M | $117.6M | ||
| Q1 25 | $503.7M | $35.9M | ||
| Q4 24 | $601.5M | $19.2M | ||
| Q3 24 | $658.1M | $36.6M | ||
| Q2 24 | $691.1M | $45.8M | ||
| Q1 24 | $791.3M | $63.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $103.7M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $4.9M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | — | $123.1M |
| Q4 25 | $671.4M | $112.9M | ||
| Q3 25 | $748.4M | $133.1M | ||
| Q2 25 | $715.3M | $149.2M | ||
| Q1 25 | $779.9M | $3.7M | ||
| Q4 24 | $872.0M | $-11.7M | ||
| Q3 24 | $962.6M | $30.8M | ||
| Q2 24 | $971.1M | $40.3M | ||
| Q1 24 | $1.0B | $52.5M |
| Q4 25 | $842.1M | $211.0M | ||
| Q3 25 | $925.3M | $224.3M | ||
| Q2 25 | $898.9M | $239.5M | ||
| Q1 25 | $986.2M | $208.8M | ||
| Q4 24 | $1.2B | $193.6M | ||
| Q3 24 | $1.2B | $224.2M | ||
| Q2 24 | $1.2B | $230.8M | ||
| Q1 24 | $1.3B | $252.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 27.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 2.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $-4.3M |
| Free Cash FlowOCF − Capex | $-69.4M | $-16.2M |
| FCF MarginFCF / Revenue | -301.6% | -102.1% |
| Capex IntensityCapex / Revenue | 0.5% | 75.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $-92.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $-4.3M | ||
| Q3 25 | $-76.9M | $-12.0M | ||
| Q2 25 | $-99.6M | $-35.1M | ||
| Q1 25 | $-148.9M | $-8.4M | ||
| Q4 24 | $-85.2M | $-19.2M | ||
| Q3 24 | $-84.8M | $14.0M | ||
| Q2 24 | $-58.2M | $-4.4M | ||
| Q1 24 | $-120.7M | $-8.8M |
| Q4 25 | $-69.4M | $-16.2M | ||
| Q3 25 | $-76.9M | $-20.4M | ||
| Q2 25 | $-99.9M | $-38.7M | ||
| Q1 25 | $-149.7M | $-17.3M | ||
| Q4 24 | $-86.2M | $-24.3M | ||
| Q3 24 | $-86.1M | $5.1M | ||
| Q2 24 | $-59.2M | $-9.9M | ||
| Q1 24 | $-123.2M | $-15.9M |
| Q4 25 | -301.6% | -102.1% | ||
| Q3 25 | -558.2% | -161.3% | ||
| Q2 25 | -701.0% | -201.7% | ||
| Q1 25 | -900.1% | -72.6% | ||
| Q4 24 | -669.4% | -112.2% | ||
| Q3 24 | -945.2% | 17.8% | ||
| Q2 24 | -850.9% | -39.0% | ||
| Q1 24 | -425.7% | -45.7% |
| Q4 25 | 0.5% | 75.1% | ||
| Q3 25 | 0.2% | 66.2% | ||
| Q2 25 | 1.7% | 18.8% | ||
| Q1 25 | 4.4% | 37.3% | ||
| Q4 24 | 7.6% | 23.5% | ||
| Q3 24 | 14.0% | 31.2% | ||
| Q2 24 | 14.5% | 21.8% | ||
| Q1 24 | 8.7% | 20.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.29× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
SPIR
Segment breakdown not available.
